Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Da Yuan Yin (DYY) is a classical Traditional Chinese Medicine (TCM) decoction, originally described in the 17th-century text *Wen Yi Lun* (Treatise on Pestilence) for the treatment of infectious diseases. Modern pharmacological research identifies DYY as a potential therapeutic for sepsis, demonstrating significant anti-inflammatory and intestinal protective effects. In preclinical models, DYY has been shown to alleviate sepsis-induced intestinal injury by suppressing the production of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6, and by promoting the expression of intestinal tight junction proteins like claudin-1, occludin, and ZO-1. Furthermore, DYY modulates the gut microbiota, specifically promoting the growth of beneficial bacteria such as Lactobacillales, which leads to increased levels of protective short-chain fatty acids (SCFAs) and reduced β-glucuronidase activity. These combined actions help maintain intestinal homeostasis and mitigate systemic organ dysfunction during sepsis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Da Yuan Yin.